IL-4 inhibits osteoclast formation through a direct action on osteoclast precursors via peroxisome proliferator-activated receptor gamma 1.
about
Osteoimmunology: interactions of the bone and immune systemVitamin D and bone health: potential mechanisms.PPARgamma mediates NSAIDs-induced upregulation of TFF2 expression in gastric epithelial cellsDisruption of Fnip1 reveals a metabolic checkpoint controlling B lymphocyte developmentInterleukin-4 inhibition of interleukin-1-induced expression of matrix metalloproteinase-3 (MMP-3) is independent of lipoxygenase and PPARgamma activation in human gingival fibroblasts.A novel osteoclast precursor cell line, 4B12, recapitulates the features of primary osteoclast differentiation and function: enhanced transfection efficiency before and after differentiation.Deletion of the alpha-arrestin protein Txnip in mice promotes adiposity and adipogenesis while preserving insulin sensitivity.The peroxisome proliferator-activated receptor (PPAR) alpha agonist fenofibrate maintains bone mass, while the PPAR gamma agonist pioglitazone exaggerates bone loss, in ovariectomized ratsEssential role for hematopoietic prostaglandin D2 synthase in the control of delayed type hypersensitivity.Role of RANKL and RANK in bone loss and arthritis.PPARγ: a circadian transcription factor in adipogenesis and osteogenesis.Electrophilic PPARγ Ligands Attenuate IL-1β and Silica-Induced Inflammatory Mediator Production in Human Lung Fibroblasts via a PPARγ-Independent Mechanism.Anti-inflammatory effects of thiazolidinediones in human airway smooth muscle cells.Resolving the Two "Bony" Faces of PPAR-gamma.Impact of targeted PPARγ disruption on bone remodeling.Adipocyte lineage cells contribute to the skin stem cell niche to drive hair cycling.Modulation of osteoclastogenesis induced by nucleoside reverse transcriptase inhibitors.'Old drugs for new applications': can orthopedic research benefit from this strategy?Immunoregulation of bone remodellingRosiglitazone induces decreases in bone mass and strength that are reminiscent of aged boneThe role of the immune system in the pathophysiology of osteoporosis.Peroxisome proliferator-activated receptor gamma is a target of progesterone regulation in the preovulatory follicles and controls ovulation in mice.Intradermal adipocytes mediate fibroblast recruitment during skin wound healing.Peroxisome proliferator-activated receptor-gamma ligands as bone turnover modulators.New insights into osteoporosis: the bone-fat connectionPeroxisome proliferator-activated receptors (PPARs) in the control of bone metabolism.Osteoimmunology: cytokines and the skeletal system.Impact of conjugated linoleic acid on bone physiology: proposed mechanism involving inhibition of adipogenesis.Complex regulation of tartrate-resistant acid phosphatase (TRAP) expression by interleukin 4 (IL-4): IL-4 indirectly suppresses receptor activator of NF-kappaB ligand (RANKL)-mediated TRAP expression but modestly induces its expression directlyProteomic approaches to study osteoclast biology.Dendritic cells enhance UHMWPE wear particle-induced osteoclast differentiation of macrophages.A review on interleukins: The key manipulators in rheumatoid arthritis.Normal human primary CD4+ T lymphocytes synthesize and release functional osteoprotegerin in vitro.Epidermal peroxisome proliferator-activated receptor gamma as a target for ultraviolet B radiation.The effect of local IL-4 delivery or CCL2 blockade on implant fixation and bone structural properties in a mouse model of wear particle induced osteolysis.Establishment of NF-κB sensing and interleukin-4 secreting mesenchymal stromal cells as an "on-demand" drug delivery system to modulate inflammation.Inflammatory cells and bone loss in rheumatoid arthritis.Stimulation of fat storage by prostacyclin and selective agonists of prostanoid IP receptor during the maturation phase of cultured adipocytes.Reciprocal effects of Interferon-γ and IL-4 on differentiation to osteoclast-like cells by RANKL or LPS.Peroxisome proliferator-activated receptor gamma agonist ligands stimulate a Th2 cytokine response and prevent acute colitis.
P2860
Q24655113-075F35C5-FEF5-4A93-B497-97F01663107EQ27690804-2C39913A-96BB-455F-9CA6-D5B51C30D352Q28167099-A8523560-A454-4478-80B0-BE510DCDA8C3Q28507620-A5B18414-CC6C-4559-B695-419234445159Q30830094-6BAE82EE-595E-4AC7-8874-21C1BACABD6AQ33459357-DF837300-10CC-456F-96F0-7F63042CA220Q33869780-ECC82A44-DD68-4E73-BBCB-25E1C330BB9CQ33912894-E50A12D0-F0F0-4A12-A73D-2524F308136EQ34597051-4217857B-CAF3-44B4-A44B-54A2C8088C1CQ34963016-5D17152A-7BA4-4D70-BDB8-07BC52D21B93Q35093192-63C06001-D030-4DA6-83D1-9A966846DD13Q35101448-D738A18C-11D1-402B-A247-E1A83EBC3B18Q35132162-2C500919-9EBC-41C4-A1A0-A4EAE6A0E8CEQ35191573-9446997B-8FDD-4661-A11D-50237D635E5BQ35648762-D9F91EF6-4ADB-416E-88A4-67288ACFD67EQ35819382-58617674-2375-4B5C-A276-721DC4F3E4B2Q36013609-193F6B41-BC8A-41FA-9F47-71FB79AE5DCAQ36056952-293746FC-163A-45A0-9F8E-324FB60A7A67Q36107934-C97B26D1-591F-4293-B6E1-C3103A63D6BCQ36157326-0F675057-ADB2-4341-BDB9-FAEFDD0A36BDQ36324969-CF9CFE42-92EE-4FA8-A279-E649A4218F7DQ36483442-D73FC93D-8D41-4361-9FA3-C86B35648A62Q36682969-EF3E9B71-E2DF-44FC-B08E-33B227132E58Q36715753-8DD2133B-60D7-430D-8CF1-E3F617A7860BQ36791099-850C8790-0435-4F84-93DB-4708B3FED09EQ36830195-EEDC25CB-20DA-4E77-8F0C-0DF5F2939826Q37235713-D9D8F42B-25F8-4F0B-94DF-F2CAAD7C1CF0Q37270218-D3B3C6C2-5C0A-487D-995A-D101939929CAQ37432210-1D041ED3-0583-43D6-AB51-D504E2AB8BB3Q38878942-ADD183FE-5046-4464-8599-AC9462E5BE8AQ38895214-CC489CED-358D-4D5B-B049-A2F6CC3CF178Q39029629-D63A2D25-FD38-48AF-BFB2-2D9B2CC1B6E1Q40044243-F69A1B9B-C912-46FA-AEBC-2166C85637FEQ40498186-D8B49991-1D6B-42E1-B29B-396F30ECB290Q41151771-E53434D0-936C-481E-91C3-1D069505E289Q42512841-C2E7C4AF-C375-43A7-9C89-0F7061D2CDE6Q42549439-EC700662-9959-4313-A811-FC01CE67CCECQ42813297-CE77CA0C-29C8-43FF-8A97-712FF39C354BQ44018514-EF5392C9-EC82-4CAF-9F82-D60BDB84CFA9Q44247093-035E8727-6944-494B-996D-26B3EDD888EB
P2860
IL-4 inhibits osteoclast formation through a direct action on osteoclast precursors via peroxisome proliferator-activated receptor gamma 1.
description
2001 nî lūn-bûn
@nan
2001 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
IL-4 inhibits osteoclast forma ...... or-activated receptor gamma 1.
@ast
IL-4 inhibits osteoclast forma ...... or-activated receptor gamma 1.
@en
IL-4 inhibits osteoclast forma ...... or-activated receptor gamma 1.
@nl
type
label
IL-4 inhibits osteoclast forma ...... or-activated receptor gamma 1.
@ast
IL-4 inhibits osteoclast forma ...... or-activated receptor gamma 1.
@en
IL-4 inhibits osteoclast forma ...... or-activated receptor gamma 1.
@nl
prefLabel
IL-4 inhibits osteoclast forma ...... or-activated receptor gamma 1.
@ast
IL-4 inhibits osteoclast forma ...... or-activated receptor gamma 1.
@en
IL-4 inhibits osteoclast forma ...... or-activated receptor gamma 1.
@nl
P2093
P2860
P356
P1476
IL-4 inhibits osteoclast forma ...... or-activated receptor gamma 1.
@en
P2093
A C Bendixen
K M Dienger
N K Shevde
T M Willson
P2860
P304
P356
10.1073/PNAS.041493198
P407
P577
2001-02-20T00:00:00Z